Overview
Indications
® LYUMJEVis indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Contraindications
When this intervention should not be used
LYUMJEV is contraindicated: during episodes of hypoglycemia. in patients with hypersensitivity to insulin lispro-aabc or any of the excipients in LYUMJEV.
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
Clinical Trials
51 trials linked to this intervention
Recent Trials
Oral Anti Diabetic Agents in the Hospital
Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes
The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Specialists
Providers who commonly manage this intervention
Health Goals
Goals connected through associated conditions
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Insulin lispro (substance)
- SNOMED CT
- 412210000
- UMLS CUI
- C0293359
- RxNorm CUI
- 86009
- Labeler
- Eli Lilly and Company
Clinical Data
This intervention maps to 13 entities in the Healos knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.